Personalizing therapies for gastric cancer: Molecular mechanisms and novel targeted therapies

World Journal of Gastroenterology

Volumn 19, Issue 38, 2013, Pages 6383-6397

  Luis, Michael ^a   Tavares, Ana ^a   Carvalho, Liliana S ^b,c   Lara Santos, Lúcio ^a   Araújo, António ^a   de Mello, Ramon Andrade ^a,b  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

Afatinib; Biomarkers; Gastric cancer; Human epidermal growth factor receptor 2; Lapatinib; Pertuzumab; Target therapies; Trastuzumab; Trastuzumab DM1

Indexed keywords

AFATINIB; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; HEAT SHOCK PROTEIN 90 INHIBITOR; IRINOTECAN; LAPATINIB; LUMINESPIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OXALIPLATIN; PACLITAXEL; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PROTEIN KINASE B; TAXANE DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; ASTHENIA; BREAST CANCER; CANCER GROWTH; CHILL; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ESOPHAGUS CANCER; FATIGUE; FEVER; HAND FOOT SYNDROME; HUMAN; HYPOTENSION; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LOADING DRUG DOSE; MAINTENANCE THERAPY; METASTASIS; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; RIGOR; SIDE EFFECT; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; WEIGHT REDUCTION;

AFATINIB; BIOMARKERS; GASTRIC CANCER; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PERTUZUMAB; TARGET THERAPIES; TRASTUZUMAB; TRASTUZUMAB-DM1;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; PATIENT SELECTION; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84885603623     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i38.6383     Document Type: Review

References (155)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
2. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L, Hung MC. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001; 3: 802-808 [PMID: 11533659 DOI: 10.1038/ ncb0901-802]
3. Williams CC, Allison JG, Vidal GA, Burow ME, Beckman BS, Marrero L, Jones FE. The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. J Cell Biol 2004; 167: 469-478 [PMID: 15534001 DOI: 10.1083/jcb.200403155]
4. Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release 2010; 146: 264-275 [PMID: 20385184 DOI: 10.1016/j.jconrel.2010.04.009]
5. Rüschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard MP, Penault-Llorca F, Nagelmeier I, Schlake W, Höfler H, Kreipe HH. HER2 diagnostics in gastric cancerguideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010; 457: 299-307 [PMID: 20665045 DOI: 10.1007/s00428-010-0952-2]
6. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, Mc-Grath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132-1139 [PMID: 2999974]
7. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232: 1644-1646 [PMID: 3012781]
8. Popescu NC, King CR, Kraus MH. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 1989; 4: 362-366 [PMID: 2565881]
9. Pinkas-Kramarski R, Shelly M, Glathe S, Ratzkin BJ, Yarden Y. Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. J Biol Chem 1996; 271: 19029-19032 [PMID: 8702572]
10. Worthylake R, Opresko LK, Wiley HS. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 1999; 274: 8865-8874 [PMID: 10085130]
11. Hendriks BS, Orr G, Wells A, Wiley HS, Lauffenburger DA. Parsing ERK activation reveals quantitatively equivalent contributions from epidermal growth factor receptor and HER2 in human mammary epithelial cells. J Biol Chem 2005; 280: 6157-6169 [PMID: 15572377 DOI: 10.1074/jbc. M410491200]
12. Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol 2001; 12 Suppl 1: S3-S8 [PMID: 11521719]
13. Park JW, Neve RM, Szollosi J, Benz CC. Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer 2008; 8: 392-401 [PMID: 18952552 DOI: 10.3816/CBC.2008. n.047]
14. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Kofler M, Jorissen RN, Nice EC, Burgess AW, Ward CW. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 2003; 11: 495-505 [PMID: 12620236]
15. Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci 2008; 65: 1566-1584 [PMID: 18259690 DOI: 10.1007/s00018-008-7440-8]
16. Telesco SE, Radhakrishnan R. Atomistic insights into regulatory mechanisms of the HER2 tyrosine kinase domain: a molecular dynamics study. Biophys J 2009; 96: 2321-2334 [PMID: 19289058 DOI: 10.1016/j.bpj.2008.12.3912]
17. Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005; 16: 273-278 [PMID: 15668283 DOI: 10.1093/annonc/ mdi064]
18. Niehans GA, Singleton TP, Dykoski D, Kiang DT. Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 1993; 85: 1230-1235 [PMID: 8101229]
19. Yan SY, Hu Y, Fan JG, Tao GQ, Lu YM, Cai X, Yu BH, Du YQ. Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. World J Gastroenterol 2011; 17: 1501-1506 [PMID: 21472111 DOI: 10.3748/wjg.v17.i11.1501]
20. Barros-Silva JD, Leitão D, Afonso L, Vieira J, Dinis-Ribeiro M, Fragoso M, Bento MJ, Santos L, Ferreira P, Rêgo S, Brandão C, Carneiro F, Lopes C, Schmitt F, Teixeira MR. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 2009; 100: 487-493 [PMID: 19156142 DOI: 10.1038/sj.bjc.6604885]
21. Dowsett M, Bartlett J, Ellis IO, Salter J, Hills M, Mallon E, Watters AD, Cooke T, Paish C, Wencyk PM, Pinder SE. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003; 199: 418-423 [PMID: 12635131 DOI: 10.1002/path.1313]
22. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792 [PMID: 11248153 DOI: 10.1056/NEJM200103153441101]
23. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672 [PMID: 16236737 DOI: 10.1056/NEJMoa052306]
24. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684 [PMID: 16236738 DOI: 10.1056/NEJMoa052122]
25. Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 2009; 27: 5685-5692 [PMID: 19884557 DOI: 10.1200/JCO.2008.21.4577]
26. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart MJ. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369: 29-36 [PMID: 17208639 DOI: 10.1016/ S0140-6736(07)60028-2]
27. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19: 1523-1529 [PMID: 18441328 DOI: 10.1093/annonc/ mdn169]
28. Okines AF, Cunningham D. Trastuzumab in gastric cancer. Eur J Cancer 2010; 46: 1949-1959 [PMID: 20542421 DOI: 10.1016/j.ejca.2010.05.003]
29. Yonemura Y, Ninomiya I, Yamaguchi A, Fushida S, Kimura H, Ohoyama S, Miyazaki I, Endou Y, Tanaka M, Sasaki T. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 1991; 51: 1034-1038 [PMID: 1670998]
30. Mizutani T, Onda M, Tokunaga A, Yamanaka N, Sugisaki Y. Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 1993; 72: 2083-2088 [PMID: 8397058]
31. Motojima K, Furui J, Kohara N, Izawa K, Kanematsu T, Shiku H. erbB-2 expression in well-differentiated adenocarcinoma of the stomach predicts shorter survival after curative resection. Surgery 1994; 115: 349-354 [PMID: 7907434]
32. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T, Nakano H. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999; 85: 1894-1902 [PMID: 10223227]
33. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 2000; 18: 2201-2209 [PMID: 10829039]
34. Pinto-de-Sousa J, David L, Almeida R, Leitão D, Preto JR, Seixas M, Pimenta A. c-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma. Int J Surg Pathol 2002; 10: 247-256 [PMID: 12490974]
35. Uchino S, Tsuda H, Maruyama K, Kinoshita T, Sasako M, Saito T, Kobayashi M, Hirohashi S. Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with longterm survival of patients. Cancer 1993; 72: 3179-3184 [PMID: 7902202]
36. Ananiev J, Gulubova M, Manolova I, Tchernev G. Prognostic significance of HER2/neu expression in gastric cancer. Wien Klin Wochenschr 2011; 123: 450-454 [PMID: 21739203 DOI: 10.1007/s00508-011-0025-9]
37. Tateishi M, Toda T, Minamisono Y, Nagasaki S. Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. J Surg Oncol 1992; 49: 209-212 [PMID: 1348293]
38. Ohguri T, Sato Y, Koizumi W, Saigenji K, Kameya T. An immunohistochemical study of c-erbB-2 protein in gastric carcinomas and lymph-node metastases: is the c-erbB-2 protein really a prognostic indicator? Int J Cancer 1993; 53: 75-79 [PMID: 8093216]
39. Lee HR, Kim JH, Uhm HD, Ahn JB, Rha SY, Cho JY, Lee JI, Lee KH, Chung HC, Roh JK, Min JS, Lee KS, Shin DH, Kim BS, Hong SW, Choi JH. Overexpression of c-ErbB-2 protein in gastric cancer by immunohistochemical stain. Oncology 1996; 53: 192-197 [PMID: 8643220]
40. Sasano H, Date F, Imatani A, Asaki S, Nagura H. Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol 1993; 24: 584-589 [PMID: 8099338]
41. Grabsch H, Sivakumar S, Gray S, Gabbert HE, Müller W. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series. Cell Oncol 2010; 32: 57-65 [PMID: 20208134 DOI: 10.3233/CLO-2009-0497]
42. Jørgensen JT, Hersom M. HER2 as a Prognostic Marker in Gastric Cancer-A Systematic Analysis of Data from the Literature. J Cancer 2012; 3: 137-144 [PMID: 22481979 DOI: 10.7150/jca.4090]
43. Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review. Int J Cancer 2012; 130: 2845-2856 [PMID: 21780108 DOI: 10.1002/ijc.26292]
44. Bozzetti C, Negri FV, Lagrasta CA, Crafa P, Bassano C, Tamagnini I, Gardini G, Nizzoli R, Leonardi F, Gasparro D, Camisa R, Cavalli S, Silini EM, Ardizzoni A. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer 2011; 104: 1372-1376 [PMID: 21487407 DOI: 10.1038/bjc.2011.121]
45. Kataoka Y, Okabe H, Yoshizawa A, Minamiguchi S, Yoshimura K, Haga H, Sakai Y. HER2 expression and its clinicopathological features in resectable gastric cancer. Gastric Cancer 2013; 16: 84-93 [PMID: 22410801 DOI: 10.1007/ s10120-012-0150-9]
46. Fornaro L, Lucchesi M, Caparello C, Vasile E, Caponi S, Ginocchi L, Masi G, Falcone A. Anti-HER agents in gastric cancer: from bench to bedside. Nat Rev Gastroenterol Hepatol 2011; 8: 369-383 [PMID: 21647199 DOI: 10.1038/nrgastro. 2011.81]
47. Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, Shah MA, Al-Batran SE. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 2012; 23: 2656-2662 [PMID: 22689179 DOI: 10.1093/annonc/ mds104]
48. Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H, Sasako M. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res 2012; 18: 5992-6000 [PMID: 22977193 DOI: 10.1158/1078-0432.CCR-12-1318]
49. Hsu JT, Chen TC, Tseng JH, Chiu CT, Liu KH, Yeh CN, Hwang TL, Jan YY, Yeh TS. Impact of HER-2 overexpression/ amplification on the prognosis of gastric cancer patients undergoing resection: a single-center study of 1,036 patients. Oncologist 2011; 16: 1706-1713 [PMID: 22143936 DOI: 10.1634/theoncologist.2011-0199]
50. Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G. HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012; 25: 637-650 [PMID: 22222640 DOI: 10.1038/modpathol.2011.198]
51. Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol 2011; 18: 53-59 [PMID: 21169738 DOI: 10.1097/PAP.0b013e3182026d72]
52. European Medicines Agency. Assessment Report for Herceptin 2010. Available from: URL: http://www.ema. europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000278/ WC500074921.pdf
53. Food and Drug Administration. U.S. BL 103792 Supplement: Trastuzumab Genentech, Inc. 2010; Available from: URL: www.accessdata.fda.gov/drugsatfda_docs/label/2010/ 103792s5250lbl.pdf
54. Stoss O, Nagelmeier I, Zielinski D, Rüschoff J. The ToGA (Trastuzumab for GAstric Cancer) Trial: Importance from a Biomarker Perspective. Available from: http://www.dako.com/ 28830_connection_15_the_toga_trastuzumab_for_gastric_can cer_trial_importance_from_a_biomarker_perspective_1.pdf
55. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, Kerbel RS. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implica-tions for signal transduction therapy of solid tumors. Am J Pathol 1997; 151: 1523-1530 [PMID: 9403702]
56. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9: 463-475 [PMID: 19536107 DOI: 10.1038/nrc2656]
57. Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990; 50: 1550-1558 [PMID: 1689212]
58. Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP, Shawver LK. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 1991; 51: 4575-4580 [PMID: 1678683]
59. Kasprzyk PG, Song SU, Di Fiore PP, King CR. Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res 1992; 52: 2771-2776 [PMID: 1349849]
60. Sakai K, Mori S, Kawamoto T, Taniguchi S, Kobori O, Morioka Y, Kuroki T, Kano K. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst 1986; 77: 1047-1052 [PMID: 3464796]
61. Fukushige S, Matsubara K, Yoshida M, Sasaki M, Suzuki T, Semba K, Toyoshima K, Yamamoto T. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol 1986; 6: 955-958 [PMID: 2430175]
62. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 2007; 59: 795-805 [PMID: 17031648 DOI: 10.1007/s00280-006-0337-z]
63. Matsui Y, Inomata M, Tojigamori M, Sonoda K, Shiraishi N, Kitano S. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int J Oncol 2005; 27: 681-685 [PMID: 16077916]
64. Kim SY, Kim HP, Kim YJ, Oh do Y, Im SA, Lee D, Jong HS, Kim TY, Bang YJ. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 2008; 32: 89-95 [PMID: 18097546]
65. Gong SJ, Jin CJ, Rha SY, Chung HC. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Lett 2004; 214: 215-224 [PMID: 15363548 DOI: 10.1016/j.canlet.2004.04.029]
66. Bang Y, Chung H, Xu J, Lordick F, Sawaki A, Lipatov O, Al-Sakaff N, See CG, Rueschoff J, Van Cutsem E. Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol 2009; 27 Suppl 15: Abstr4556
67. Cortés-Funes H, Rivera F, Alés I, Márquez A, Velasco A, Colomer R, García-Carbonero R, Sastre J, Guerra J, Grávalos C. Phase II of trastuzumab and cisplatin in patients with advanced gastric cancer with HER2/neu overexpression/ amplification. J Clin Oncol 2007; 25: 1-2
68. Egamberdiev D, Djuraev M, Tuydjanova K, Nematov O. Our experience in the use of trastuzumab in patients with advanced stomach cancer. Ann Oncol 2010; 21 Suppl 8: S839
69. Grávalos C, Gómez-Martín C, Rivera F, Alés I, Queralt B, Márquez A, Jiménez U, Alonso V, García-Carbonero R, Sastre J, Colomer R, Cortés-Funes H, Jimeno A. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clin Transl Oncol 2011; 13: 179-184 [PMID: 21421462 DOI: 10.1007/s12094-011-0637-6]
70. Boers JE, Meeuwissen H, Methorst N. HER2 status in gastrooesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology 2011; 58: 383-394 [PMID: 21323962 DOI: 10.1111/j.1365-2559.2011.03760.x]
71. He C, Bian XY, Ni XZ, Shen DP, Shen YY, Liu H, Shen ZY, Liu Q. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. World J Gastroenterol 2013; 19: 2171-2178 [PMID: 23599643]
72. Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, Bangs CD, Cherry AM, Pai RK. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol 2012; 20: 13-24 [PMID: 21617522 DOI: 10.1097/ PAI.0b013e31821c821c]
73. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. Lancet 2010; 376: 687-697 [PMID: 20728210 DOI: 10.1016/S0140-6736(10)61121-X]
74. De Vita F, Giuliani F, Silvestris N, Catalano G, Ciardiello F, Orditura M. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treat Rev 2010; 36 Suppl 3: S11-S15 [PMID: 21129604 DOI: 10.1016/S0305-7372(10)70014-1]
75. Moelans CB, van Diest PJ, Milne AN, Offerhaus GJ. Her-2/ neu testing and therapy in gastroesophageal adenocarcinoma. Patholog Res Int 2011; 2011: 674182 [PMID: 21188213]
76. Hede K. Gastric cancer: trastuzumab trial results spur search for other targets. J Natl Cancer Inst 2009; 101: 1306-1307 [PMID: 19755679 DOI: 10.1093/jnci/djp341]
77. Polkowski W, van Sandick JW, Offerhaus GJ, ten Kate FJ, Mulder J, Obertop H, van Lanschot JJ. Prognostic value of Laurén classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol 1999; 6: 290-297 [PMID: 10340889]
78. Yamashita K, Sakuramoto S, Watanabe M. Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications. Surg Today 2011; 41: 24-38 [PMID: 21191688 DOI: 10.1007/s00595-010-4370-5]
79. Bystricky B, Okines A, Cunningham D. Targeting Her-2 in gastric cancer-incorporation of trastuzumab into the treatment of operable disease. Gastrointestinal Cancer: Targets and Therapy 2011; 1: 41-52
80. Radiation Therapy Oncology Group. Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer. 2010; Available from: URL: http://clinicaltrials.gov/ct2/show/ NCT01196390
81. Hoffmann-La Roche. A Study of Capecitabine (Xeloda) in Combination With Trastuzumab (Herceptin) and Oxaliplatine in Patients With Resectable Gastric Cancer. 2010; Available from: URL: http://clinicaltrials.gov/ct2/show/ NCT01130337
82. Carvalho R, Milne AN, van Rees BP, Caspers E, Cirnes L, Figueiredo C, Offerhaus GJ, Weterman MA. Early-onset gastric carcinomas display molecular characteristics distinct from gastric carcinomas occurring at a later age. J Pathol 2004; 204: 75-83 [PMID: 15307140 DOI: 10.1002/path.1602]
83. Milne AN, Carvalho R, Morsink FM, Musler AR, de Leng WW, Ristimäki A, Offerhaus GJ. Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers. Mod Pathol 2006; 19: 564-572 [PMID: 16474375 DOI: 10.1038/modpathol.3800563]
84. Milne AN, Sitarz R, Carvalho R, Carneiro F, Offerhaus GJ. Early onset gastric cancer: on the road to unraveling gastric carcinogenesis. Curr Mol Med 2007; 7: 15-28 [PMID: 17311530]
85. Rose JS, Bekaii-Saab TS. New developments in the treatment of metastatic gastric cancer: focus on trastuzumab. Onco Targets Ther 2011; 4: 21-26 [PMID: 21552412 DOI: 10.2147/OTT. S10188]
86. Extra JM, Antoine EC, Vincent-Salomon A, Delozier T, Kerbrat P, Bethune-Volters A, Guastalla JP, Spielmann M, Mauriac L, Misset JL, Serin D, Campone M, Hebert C, Remblier C, Bergougnoux L, Campana F, Namer M. Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist 2010; 15: 799-809 [PMID: 20671105 DOI: 10.1634/theoncologist.2009-0029]
87. von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W, Baumann KH, Clemens MR, Duerr R, Uleer C, Andersson M, Stein RC, Nekljudova V, Loibl S. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 2009; 27: 1999-2006 [PMID: 19289619 DOI: 10.1200/ JCO.2008.19.6618]
88. Jahanzeb M. Continuing trastuzumab beyond progression. J Clin Oncol 2009; 27: 1935-1937 [PMID: 19289613 DOI: 10.1200/JCO.2008.20.8215]
89. Valabrega G, Aglietta M, Montemurro F. Trastuzumab beyond disease progression: case closed? J Clin Oncol 2009; 27: e121-e12; author reply e121-e12; [PMID: 19687323 DOI: 10.1200/JCO.2009.23.8873]
90. Boku N. HER2-positive gastric cancer. Gastric Cancer 2013; Epub ahead of print [PMID: 23563986 DOI: 10.1007/s10120-013-0252-z]
91. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20 [PMID: 16822992 DOI: 10.1056/NEJMoa055531]
92. Okines AF, Thompson LC, Cunningham D, Wotherspoon A, Reis-Filho JS, Langley RE, Waddell TS, Noor D, Eltahir Z, Wong R, Stenning S. Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann Oncol 2013; 24: 1253-1261 [PMID: 23233651 DOI: 10.1093/annonc/mds622]
93. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 1999; 229: 303-308 [PMID: 10077040]
94. Sbitti Y, Essaidi I, Debbagh A, Kadiri H, Oukabli M, Moussaid Y, Slimani K, Fetohi M, Elkaoui H, Albouzidi A, Mahi M, Ali AA, Ichou M, Errihani H. Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma? World J Surg Oncol 2011; 9: 112 [PMID: 21955806 DOI: 10.1186/1477-7819-9-112]
95. Wang J, Saukel GW, Garberoglio CA, Srikureja W, Hsueh CT. Pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen in gastric cancer: a case report. J Hematol Oncol 2010; 3: 31 [PMID: 20828403 DOI: 10.1186/1756-8722-3-31]
96. Khaledy C, Ashouri S, Hiyama D, Sadeghi S. Trastuzumab based Neoadjuvant chemotherapy for Locally Advanced HER2 Over Expressing Gastric Adenocarcinoma. Proceedings of UCLA Healthcare 2013; 17
97. Harris KA, Washington CB, Lieberman G, Lu JF, Mass R, Bruno R. A population pharmacokinetic model for trastuzumab (Herceptin) and implications for clinical dosing. Proc Am Soc Clin Oncol 2002; 21: Abstr488
98. Leyland-Jones B, Gelmon K, Ayoub JP, Arnold A, Verma S, Dias R, Ghahramani P. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003; 21: 3965-3971 [PMID: 14507946 DOI: 10.1200/JCO.2003.12.109]
99. Levêque D, Gigou L, Bergerat JP. Clinical pharmacology of trastuzumab. Curr Clin Pharmacol 2008; 3: 51-55 [PMID: 18690878]
100. Croxtall JD, McKeage K. Trastuzumab: in HER2-positive metastatic gastric cancer. Drugs 2010; 70: 2259-2267 [PMID: 21080742 DOI: 10.2165/11205900-000000000-00000]
101. Barok M, Tanner M, Köninki K, Isola J. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett 2011; 306: 171-179 [PMID: 21458915 DOI: 10.1016/j.canlet.2011.03.002]
102. Zhou XX, Ji F, Zhao JL, Cheng LF, Xu CF. Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells. J Gastroenterol Hepatol 2010; 25: 1266-1275 [PMID: 20594254 DOI: 10.1111/j.1440-1746.2010.06287.x]
103. Meza-Junco J, Au HJ, Sawyer MB. Critical appraisal of trastuzumab in treatment of advanced stomach cancer. Cancer Manag Res 2011; 3: 57-64 [PMID: 21556317 DOI: 10.2147/ CMR.S12698]
104. Bovelli D, Plataniotis G, Roila F. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol 2010; 21 Suppl 5: v277-v282 [PMID: 20555097 DOI: 10.1093/annonc/ mdq200]
105. Fiuza M, Magalhães A. Trastuzumab and Cardiotoxicity. In: Fiuza M, editor. Cardiotoxicity of Oncologic Treatments: InTech. Rijeka: InTech Editor, 2012: 122-152
106. Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51 [PMID: 17611206 DOI: 10.1056/NEJMra043186]
107. Gajria D, Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther 2011; 11: 263-275 [PMID: 21342044 DOI: 10.1586/era.10.226]
108. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006; 3: 269-280 [PMID: 16683005 DOI: 10.1038/ncponc0509]
109. Okines AF, Cunningham D. Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer. Therap Adv Gastroenterol 2012; 5: 301-318 [PMID: 22973416 DOI: 10.1177/1756283X124 50246]
110. de Mello RA, de Vasconcelos A, Ribeiro RA, Pousa I, Afonso N, Pereira D, Rodrigues H. Insight into p95HER2 in breast cancer: molecular mechanisms and targeted therapies. Recent Pat DNA Gene Seq 2012; 6: 56-63 [PMID: 22239685]
111. Fessler SP, Wotkowicz MT, Mahanta SK, Bamdad C. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells. Breast Cancer Res Treat 2009; 118: 113-124 [PMID: 19415485 DOI: 10.1007/s10549-009-0412-3]
112. Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, Papakostas P, Aravantinos G, Rigakos G, Efstratiou I, Petraki K, Bafaloukos D, Kostopoulos I, Pectasides D, Kalogeras KT, Skarlos D, Fountzilas G. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat 2011; 128: 447-456 [PMID: 21594665 DOI: 10.1007/s10549-011-1572-5]
113. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6: 117-127 [PMID: 15324695 DOI: 10.1016/j.ccr.2004.06.022]
114. Lu CH, Wyszomierski SL, Tseng LM, Sun MH, Lan KH, Neal CL, Mills GB, Hortobagyi GN, Esteva FJ, Yu D. Pre-clinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 2007; 13: 5883-5888 [PMID: 17908983 DOI: 10.1158/1078-0432.CCR-06-2837]
115. Andre F, Campone M, O'Regan R, Manlius C, Massacesi C, Sahmoud T, Mukhopadhyay P, Soria JC, Naughton M, Hurvitz SA. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 2010; 28: 5110-5115 [PMID: 20975068 DOI: 10.1200/JCO.2009.27.8549]
116. Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, Xiong Y, Zhang S, Krop IE, Winer EP, Kindelberger DW, Coviello J, Sahin AA, Nuñez R, Hortobagyi GN, Yu D, Esteva FJ. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumabbased therapy. J Clin Oncol 2011; 29: 3126-3132 [PMID: 21730275 DOI: 10.1200/JCO.2010.32.2321]
117. Sáez R, Molina MA, Ramsey EE, Rojo F, Keenan EJ, Albanell J, Lluch A, García-Conde J, Baselga J, Clinton GM. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 2006; 12: 424-431 [PMID: 16428482 DOI: 10.1158/1078-0432.CCR-05-1807]
118. Sperinde J, Jin X, Banerjee J, Penuel E, Saha A, Diedrich G, Huang W, Leitzel K, Weidler J, Ali SM, Fuchs EM, Singer CF, Köstler WJ, Bates M, Parry G, Winslow J, Lipton A. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin Cancer Res 2010; 16: 4226-4235 [PMID: 20664024 DOI: 10.1158/1078-0432. CCR-10-0410]
119. Gajria D, Gonzalez J, Feigin K, Patil S, Chen C, Theodoulou M, Drullinsky P, D'Andrea G, Lake D, Norton L, Hudis CA, Traina TA. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2012; 131: 111-116 [PMID: 21898114 DOI: 10.1007/s10549-011-1749-y]
120. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010; 28: 1124-1130 [PMID: 20124187 DOI: 10.1200/ JCO.2008.21.4437]
121. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007; 445: 437-441 [PMID: 17206155 DOI: 10.1038/nature05474]
122. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX, Stern HM. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008; 68: 5878-5887 [PMID: 18632642 DOI: 10.1158/0008-5472.CAN-08-0380]
123. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001; 93: 1852-1857 [PMID: 11752009]
124. Browne BC, Crown J, Venkatesan N, Duffy MJ, Clynes M, Slamon D, O'Donovan N. Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. Ann Oncol 2011; 22: 68-73 [PMID: 20647220 DOI: 10.1093/annonc/mdq349]
125. Pazo Cid RA, Antón A. Advanced HER2-positive gastric cancer: current and future targeted therapies. Crit Rev Oncol Hematol 2013; 85: 350-362 [PMID: 23021388 DOI: 10.1016/ j.critrevonc.2012.08.008]
126. Smyth EC, Cunningham D. Targeted therapy for gastric cancer. Curr Treat Options Oncol 2012; 13: 377-389 [PMID: 22552927 DOI: 10.1007/s11864-012-0192-6]
127. Van Cutsem E, Yeh K, Bang Y. Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1. J Clin Oncol 2012; 30 Suppl 4: Abstr LBA3
128. Lu C, Liu D, Jin J, Deokar H, Zhang Y, Buolamwini JK, Yu X, Yan C, Chen X. Inhibition of gastric tumor growth by a novel Hsp90 inhibitor. Biochem Pharmacol 2013; 85: 1246-1256 [PMID: 23415900 DOI: 10.1016/j.bcp.2013.02.003]
129. Nahta R, O'Regan RM. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/ Akt/mTOR pathway. Clin Breast Cancer 2010; 10 Suppl 3: S72-S78 [PMID: 21115425 DOI: 10.3816/CBC.2010.s.015]
130. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743 [PMID: 17192538 DOI: 10.1056/NEJMoa064320]
131. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, Arteaga CL. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007; 13: 4909-4919 [PMID: 17699871 DOI: 10.1158/1078-0432. CCR-07-0701]
132. Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, Fejzo MS, Hecht JR, Slamon DJ, Finn RS. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 2010; 16: 1509-1519 [PMID: 20179222 DOI: 10.1158/1078-0432. CCR-09-1112]
133. Zagouri F, Papadimitriou CA, Dimopoulos MA, Pectasides D. Molecularly targeted therapies in unresectable-metastatic gastric cancer: a systematic review. Cancer Treat Rev 2011; 37: 599-610 [PMID: 21676549 DOI: 10.1016/j.ctrv.2011.03.007]
134. Galsky MD, Von Hoff DD, Neubauer M, Anderson T, Fleming M, Nagarwala Y, Mahoney JM, Midwinter D, Vocila L, Zaks TZ. Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Invest New Drugs 2012; 30: 695-701 [PMID: 20857170 DOI: 10.1007/s10637-010-9541-0]
135. Iqbal S, Goldman B, Fenoglio-Preiser CM, Lenz HJ, Zhang W, Danenberg KD, Shibata SI, Blanke CD. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol 2011; 22: 2610-2615 [PMID: 21415234 DOI: 10.1093/annonc/mdr021]
136. Hecht J, Urba S, Koehler M. Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: phase II efficacy and biomarker analyses. ASCO Proceedings of the Gastrointestinal Cancers Symposium 2008; 43: Abstr48
137. Pishvaian M, Sakaeva D, Hsieh R. A global, multi-center phase II trial of lapatinib plus capecitabine in gastric cancer. J Clin Oncol 2011; 29 Suppl 4: Abstr 88
138. Lenz H, Zhang J, Kemner AM, Kaneko T, Yang D, Franklin N. Lapatinib capecitabine in advanced gastric cancer: An openlabel phase II study of non ERBB2-targeted disease. Ann Oncol 2010; 21 Suppl 8: S817
139. LOGiC. Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib 2008. Available from: URL: http://clinicaltrials.gov/ct2/show/NCT00680901
140. Hecht JR, Urba SG, Koehler M, Ellis C, Gagnon R, Kemner A. Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: Phase II efficacy and biomarker analyses. Proceedings of the Gastrointestinal Cancers Symposium American Society of Clinical Oncology; 2008, Jan 25-27; Orlando Florida, USA. Alexandria: Proc ASCO GI, 2008: 43
141. Kline GS. Lapatinib in Combination With Weekly Paclitaxel in Patients With ErB2 Amplified Advanced Gastric Cancer 2007. Available from: URL: http://clinicaltrials.gov/ct2/ show/NCT00486954
142. Satoh T, Bang Y, Wang J, Xu J, Chung HC, Yeh K, Chen J, Mukaiyama A, Yoshida P, Ohtsu A. Interim safety analysis from TYTAN: A phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer. J Clin Oncol 2010; 28: 4057
143. Shitara K, Mizota A, Yatabe Y, Kondo C, Nomura M, Yokota T, Takahari D, Ura T, Muro K. Lapatinib plus trastuzumab for a patient with heavily pre-treated gastric cancer that progressed after trastuzumab. Jpn J Clin Oncol 2011; 41: 663-665 [PMID: 21335337 DOI: 10.1093/jjco/hyr014]
144. Gianni L, Lladó A, Bianchi G, Cortes J, Kellokumpu-Lehtinen PL, Cameron DA, Miles D, Salvagni S, Wardley A, Goeminne JC, Hersberger V, Baselga J. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28: 1131-1137 [PMID: 20124183 DOI: 10.1200/JCO.2009.24.1661]
145. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-119 [PMID: 22149875 DOI: 10.1056/NEJMoa1113216]
146. Yamashita-Kashima Y, Iijima S, Yorozu K, Furugaki K, Kurasawa M, Ohta M, Fujimoto-Ouchi K. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res 2011; 17: 5060-5070 [PMID: 21700765 DOI: 10.1158/1078-0432.CCR-10-2927]
147. Hoffmann-La Roche. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer 2011. Available from: URL: http://clinicaltrials.gov/ct2/show/ NCT01461057
148. Burris HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011; 29: 398-405 [PMID: 21172893 DOI: 10.1200/JCO.2010.29.5865]
149. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-1791 [PMID: 23020162 DOI: 10.1056/NEJMoa1209124]
150. Nam HJ, Ching KA, Kan J, Kim HP, Han SW, Im SA, Kim TY, Christensen JG, Oh DY, Bang YJ. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer. Mol Cancer Ther 2012; 11: 439-451 [PMID: 22135232 DOI: 10.1158/1535-7163. MCT-11-0494]
151. Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, Munster P, Frakes L, Kelly S, Garcia AA, Cleator S, Uttenreuther-Fischer M, Jones H, Wind S, Vinisko R, Hickish T. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat 2012; 133: 1057-1065 [PMID: 22418700 DOI: 10.1007/s10549-012-2003-y]
152. Hamilton E, Blackwell K, Hobeika AC, Clay TM, Broadwater G, Ren XR, Chen W, Castro H, Lehmann F, Spector N, Wei J, Osada T, Lyerly HK, Morse MA. Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]. J Transl Med 2012; 10: 28 [PMID: 22325452 DOI: 10.1186/1479-5876-10-28]
153. Loewenstein PM, Green M. Expression of the Adenovirus Early Gene 1A Transcription-Repression Domain Alone Downregulates HER2 and Results in the Death of Human Breast Cancer Cells Upregulated for the HER2 Proto-Oncogene. Genes Cancer 2011; 2: 737-744 [PMID: 22207899 DOI: 10.1177/1947601911426570]
154. Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. (212)Pbradioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease. Mol Cancer Ther 2012; 11: 639-648 [PMID: 22238365 DOI: 10.1158/1535-7163. MCT-11-0671]
155. Milenic DE, Wong KJ, Baidoo KE, Nayak TK, Regino CA, Garmestani K, Brechbiel MW. Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials. MAbs 2010; 2: 550-564 [PMID: 20716957 DOI: 10.4161/ mabs.2.5.13054]